These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38335531)

  • 1. Antithrombotic Stewardship: Evaluation of Platelet Reactivity-Guided Cangrelor Dosing Using the VerifyNow Assay.
    Connery A; Ahuja T; Katz A; Arnouk S; Zhu E; Papadopoulos J; Rao S; Merchan C
    J Cardiovasc Pharmacol; 2024 May; 83(5):482-489. PubMed ID: 38335531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
    Bowman S; Gass J; Weeks P
    Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.
    Lattuca B; Silvain J; Yan Y; Pouillot C; Cuisset T; Cayla G; Henry P; Diallo A; Elhadad S; Rangé G; Lhermusier T; Boueri Z; Motreff P; Carrié D; Vicaut E; Montalescot G; Collet JP
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e007749. PubMed ID: 31694410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
    Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
    Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
    Giustino G; Redfors B; Kirtane AJ; Mehran R; Dangas GD; Witzenbichler B; Neumann FJ; Weisz G; Généreux P; Maehara A; McAndrew T; Farhan S; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Gurbel P; Ben-Yehuda O; Stone GW
    JACC Cardiovasc Interv; 2018 Jul; 11(13):1277-1286. PubMed ID: 29908967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
    Angiolillo DJ; Schneider DJ; Bhatt DL; French WJ; Price MJ; Saucedo JF; Shaburishvili T; Huber K; Prats J; Liu T; Harrington RA; Becker RC
    J Thromb Thrombolysis; 2012 Jul; 34(1):44-55. PubMed ID: 22569899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
    Lee JH; Ahn SG; Park B; Park SW; Kang YS; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J
    Korean J Intern Med; 2015 Sep; 30(5):620-8. PubMed ID: 26354056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of platelet reactivity assessment in dual antiplatelet prophylaxis after transcatheter aortic valve implantation.
    Czerwińska-Jelonkiewicz K; Witkowski A; Dąbrowski M; Piotrowski W; Hryniewiecki T; Stępińska J
    Arch Cardiovasc Dis; 2018 Apr; 111(4):233-245. PubMed ID: 29126843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
    Capodanno D; Milluzzo RP; Angiolillo DJ
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.
    Rosengart TK; Romeiser JL; White LJ; Fratello A; Fallon E; Senzel L; Shroyer AL
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1259-1266, 1266.e1; discussion 1266. PubMed ID: 23953984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support.
    Pluenneke JC; Mohamed AM; Hayes CH; Berry TP; Thomas EL; Zhurav L; Kozinn JB; Haines MM; Welge JA
    J Cardiothorac Vasc Anesth; 2023 Dec; 37(12):2511-2516. PubMed ID: 37775345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.